Disease‐modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta‐analysis

Abstract

Multiple sclerosis (MS) is a complex neurological disease that is characterized by inflammation, demyelination, gliosis, and neuronal loss. Based on the disease course, it groups into seven categories, of which relapsing-remitting MS is the most common. 1 Clinical symptoms typically first develop in young adults. Gradually, a progressive course then ensues with permanent disability in 10 to

Ensemble machine learning identifies genetic loci associated with future worsening of disability in people with multiple sclerosis

“…6 ), a person with MS having 2 alleles for rs12722559 and ≥ 1 allele for rs4808760 has a faster rate of disability accrual (expected time of transitioning is ~ 33 days), compared to some one having ≤ 1 allele for rs10271373 and > 1 allele for rs12434551 (expected time of transitioning is 270 days). Further, incorporating recently established clinical biomarkers such as brain MRI T2L load, baseline blood CSF parameters 18 , 19 and NFL 18 , 20 ; and disease modifiable risk factors such as VitD treatments and type of DMT use 7 – 10 , will enhance the clinical utility of these decision rules. Additionally, combining the effects of the 28 variants into a standard polygenic risk score (PRS) may further improve the predictive accuracy of the derived ensembles.…”

“…The focus has been to develop strategies and interventions to manage or slow disability progression, and to improve the quality of life of affected individuals. Disease modifying therapies (DMTs) 7 – 10 and vitamin D treatments (VitD) 11 – 15 are currently the only avenues used to prevent relapses, new brain and spinal cord lesions, and perhaps prevent worsening of neurological disability 16 , 17 .…”